ALBUQUERQUE, N.M. (KRQE) – The Lovelace Heart Hospital is celebrating the new addition of their 1,000th heart device. Called ...

Click to share on Facebook (Opens in new window) Click to email a link to a friend (Opens in new window) Click to print (Opens in new window) Click to share on X (Opens in new window) The ...

For more information about the updated device, please call the ProCare Odessa Heart Institute at 432-337-3117 or visit the Watchman website here. For the latest news, weather, sports, and ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Boston Scientific Corporation announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device. Key findings ...

(BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrirl Appendage Closure (LAAC) Device. The device demonstrated superior ...

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

The OPTION trial revealed non-inferior efficacy for all-cause death, stroke, or systemic embolism at 36 months. The WATCHMAN ...

The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their ...

(BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrirl Appendage Closure (LAAC) Device. The device demonstrated superior ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.